**THURSDAY APRIL 9\textsuperscript{th} 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 12.30</td>
<td><strong>THE NATURE OF SE: EXPERIMENTAL ASPECTS</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: D. Kullmann (United Kingdom) and J. Kapur (USA)</td>
</tr>
<tr>
<td>08.30 - 08.40</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>S. Shorvon (United Kingdom) and E. Trinka (Austria)</td>
</tr>
<tr>
<td>08.40 - 09.15</td>
<td>Is hypoxia important in status epilepticus?</td>
</tr>
<tr>
<td></td>
<td>G. Biagini (Italy)</td>
</tr>
<tr>
<td>09.15 – 09.50</td>
<td>Structural and functional changes in astrocytes following SE</td>
</tr>
<tr>
<td></td>
<td>K. Wilcox (USA)</td>
</tr>
<tr>
<td>09.50 - 10.20</td>
<td>Coffee Break</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Lowenstein (USA) and A. Rossetti (Switzerland)</td>
</tr>
<tr>
<td>10.20 – 10.55</td>
<td>What are the physiological bases of GPE\textsubscript{D}s and other EEG patterns in status epilepticus?</td>
</tr>
<tr>
<td></td>
<td>M. van Putten (The Netherlands)</td>
</tr>
<tr>
<td>10.55 - 11.30</td>
<td>Is spreading depression important in status epilepticus?</td>
</tr>
<tr>
<td></td>
<td>J. Dreier (Germany)</td>
</tr>
<tr>
<td>11.30 - 12.05</td>
<td>What does burst suppression really mean?</td>
</tr>
<tr>
<td></td>
<td>F. Amzica (Canada)</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
12.30 – 13.30  SATELLITE SYMPOSIUM
STATUS EPILEPTICUS – FROM BENCH TO BEDSIDE –
CHALLENGES FOR TRANSLATING NEW MECHANISMS INTO
NEW TREATMENTS
(Sponsored by Industry)

Co-Chairs: E. Trinka (Austria) and S. Shorvon (United Kingdom)

12.30 – 12.35  Introduction
E. Trinka (Austria) and S. Shorvon (United Kingdom)

12.35 – 13.00  Animal models of status epilepticus: perspectives on predictability and translation
M. Walker (United Kingdom)

13.00 – 13.25  Clinical trials for status epilepticus: perspectives on feasibility
A. Rossetti (Switzerland)

13.25 – 13.30  Concluding remarks
E. Trinka (Austria) and S. Shorvon (United Kingdom)

13:30 – 14:00  PANEL DISCUSSION
The conference perspective on translating new mechanisms into new treatments

14.00 - 17.30  THE NATURE OF SE: CLINICAL ASPECTS

Chair: H. Cross (United Kingdom) and R. Guerrini (Italy)

14.00 - 14.30  Genetic defects of mitochondrial pathways leading to status epilepticus?
S. Rahman (United Kingdom)

14.30 - 15.00  Status epilepticus, inflammation and blood brain barrier disruption
J. Gorter (The Netherlands)

15.00 - 15.30  P2X receptor as a link between hyperexcitability and neuroinflammation in status epilepticus
D. Henshall (Ireland)

15.30 - 16.00  Coffee Break
Chair: N. Bharucha (India) and C. Wasterlain (USA)

16.00 - 16.30 Status epilepticus as a phenotype of genetic mutations  
S. Shorvon (United Kingdom)

16.30 – 17.00 Predicting the outcome of status epilepticus  
M. Leitinger (Austria)

17.00 - 17.30 Expert Panel Discussion:  
The experimental and clinical nature of status epilepticus  
Chair: E. Trinka (Austria)  
M. Cook (Australia), R. Guerrini (Italy), J. Kapur (USA), D. Lowenstein (USA), A. Rossetti (Switzerland), C. Wasterlain (USA)

19.30 - 23.00 RECEPTION AND DINNER (Royal College of Physicians)

FRIDAY APRIL 10th 2015

08.30 - 12.30 CLINICAL ASPECTS OF STATUS EPILEPTICUS

Chair: M. Koepp (United Kingdom) and D. Lowenstein (USA)

08.30 - 09.05 The nature of neonatal SE  
D. Dlugos (USA)

09.05 - 09.40 Drug induced status epilepticus  
H. Cock (United Kingdom)

09.40 - 10.15 Can anaesthetic treatment worsen outcome in status epilepticus?  
R. Sutter (Switzerland)

10.15 - 10.45 Coffee Break  
Chair: T. Bleck (USA) and R. Guerrini (Italy)

10.45 - 11.20 Systemic complications of status epilepticus  
S. Hocker (USA)

11.20 - 11.55 Audit of treatment in refractory status epilepticus  
M. Ferlisi (Italy)
11.55 – 14.00  CONFERENCE PHOTOGRAPH, POSTERS AND LUNCH

14.00 – 15.00  MINI-SYMPOSIUM: CANNABINOIDS AND STATUS EPILEPTICUS

14.00 – 14.30  Cannabinoid pharmacology in preclinical models of seizure, status and epilepsy
B. J. Whalley (United Kingdom)

14.30 – 15.00  Emerging clinical effects of cannabinoids in epilepsy
H. Cross (United Kingdom)

15.00 - 15.30  Tea Break

15.30 - 17.15  ELECTROGRAPHIC SE

Chair:  R. Pressler (United Kingdom) and A. Rossetti (Switzerland)

15.30 - 16.00  Electrographic status epilepticus in critically ill children: epidemiology and outcome
N. Abend (USA)

16.00 - 16.30  Outcome of electrographic status epilepticus
T. Loddenkemper (USA)

16.30 - 17.00  Which EEG Patterns in Coma are nonconvulsive status epilepticus?
E. Trinka (Austria)

17.00 – 17.15  GPEDs and SE – a matter of frequency?
M. Koutroumanides (United Kingdom)

17.15 – 18.00  DEBATE

Chair:  S. Shorvon (United Kingdom)

Motion: Should PEDs (and similar EEG Patterns) in post-anoxic status epilepticus be treated?
Pro:  L. Hirsch (USA)
Contra:  P. Kaplan (USA)
### NOVEL ASPECTS IN THE DRUG TREATMENT OF SE

Chair: C. Wasterlain (USA)

**08.45 – 09.00**

**Invited lecture: System mechanisms of anti-epileptic protection**
V. Karlov (Moscow)

**09.00 – 09.30**

**Intranasal therapies of acute seizures**
R. Kälviainen (Finland)

**09.30 – 10.00**

**Intramuscular and rectal therapies of acute seizures**
I. Leppik (USA)

**10.00 – 10.30**

**SPD and valnoctamide**
M. Bialer (Israel)

**10.30 – 11.00**

Coffee Break

### NEUROSTEROIDS MINI SYMPOSIUM
(Sponsored by Industry)

**11.00 – 11.30**

**SAGE 689, a second generation neuroactive steroid for status epilepticus**
A. Robichaud (USA)

**11.30 – 12.00**

**SAGE 547, for super refractory status epilepticus; a clinical update**
S. Kanes (USA)

**12.00 – 13.45**

**LUNCH & SATELLITE SYMPOSIUM**
(Sponsored by Industry)
Programme to follow
13.45 - 16.15  NOVEL ASPECTS IN THE DRUG TREATMENT OF SE

Chair: J. Kapur (USA) and T. Bleck (USA)

13.45 - 14.15  New experimental therapies in pre-clinical development
M. Walker (United Kingdom)

14.15 - 14.45  Single v. combinational therapies in SE
W. Lösch (Germany)

14.45 – 15.15  A tale of two receptors: synergistic drug combinations for status epilepticus
C. Wasterlain (USA)

15.15 – 15.45  Propofol Hemisuccinate
M. Rogawski (USA)

15.45 – 16.15  Lacosamide
A. Husain (USA)

16.15   END OF COLLOQUIUM AND TEA